Immune checkpoint blockade: a common denominator approach to cancer therapy.
Immune checkpoint blockade: a common denominator approach to cancer therapy.
S. Topalian,C. Drake,D. Pardoll
2015 · DOI: 10.1016/j.ccell.2015.03.001
Cancer Cell · 3,719 Citações
TLDR
The immune system recognizes and is poised to eliminate cancer but is held in check by inhibitory receptors and ligands, so drugs interrupting immune checkpoints, such as anti-CTLA-4, anti-PD-1, and others in early development, can unleash anti-tumor immunity and mediate durable cancer regressions.